A new kind of specialist is needed at academic medical centers to cope with public health emergencies such as the COVID-19 pandemic: physician-public health practitioners.
A new kind of specialist is needed at academic medical centers to cope with public health emergencies such as the COVID-19 pandemic, argued the authors of an opinion piece in JAMA Health Forum in March.
These “physician-public health practitioners” would be trained in how to build partnerships with community organizations, translate scientific information and provide technical assistance to outsider organizations, wrote Kirsten Bibbins-Domingo, Ph.D., M.D., M.A.S., and Alicia Fernandez, M.D., of the University of California, San Francisco, School of Medicine.
As Bibbins-Domingo and Fernandez note, many academic medical centers have ventured into population health with its focus on prevention and broader issues affecting people’s health status, including upstream, social determinants. In some cases, those population health efforts and programs have led to formal and informal partnerships with community organizations and departments of health.
“These movements in academic medical centers are laudable and, based on our experience, argue for more formal training and recognition of the academic physicians who are leading and partnering with others to advance population health,” they argued.
Bibbins-Domingo and Fernandez point to the 1910 Flexner report as putting U.S. medical school on the path toward research excellence and “enshrinement of the biomedical model of clinical care.” Another Flexner-like overhaul of American medical schools is not in the offing, but they say in light of the 21st century healthcare challenges — they mention obesity, the opioid epidemic and infectious diseases — it is time to invest in another kind of academic clinical leader.
Phase 3 Trial of Vertex’s Islet Cell Therapy for Type 1 Diabetes in Under Way
April 23rd 2025Zimislecel is an allogeneic stem cell-derived islet cell therapy that could eliminate the need for insulin in those who have type 1 diabetes. Regulatory submissions are expected in 2026, and if approved, would be the second cell therapy for type 1 diabetes.
Read More
Conversations With Perry and Friends
April 14th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. His guest this episode is John Baackes, the former CEO of L.A. Care Health Plan.
Listen
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
Experts Explore Causes and Care for Chronic Itch
April 22nd 2025In a recent discussion with Managed Healthcare Executive, three leading dermatologists and itch experts—Shawn Kwatra, M.D., Brian Kim, M.D., and Gil Yosipovitch, M.D.—shared where the science is going, what’s holding it back and how the healthcare system can better support patients.
Read More